Switch from TDF to TAF does not affect viral suppression in chronic HBV
10 Sep 2020
byRoshini Claire Anthony
In virologically suppressed patients with chronic hepatitis B virus (HBV) infection, switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) did not affect their rates of viral suppression, according to the final 96-week analysis of a phase III study.